Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain

Abstract

Myeloid malignancies (MMs) are a heterogeneous group of hematologic malignancies presenting different incidence, prognosis and survival.1–3 Changing classifications (FAB 1994, WHO 2001 and WHO 2008) and few available epidemiological data complicate incidence comparisons.4,5 Taking this into account, the aims of the present study were: a) to calculate the incidence rates and trends of MMs in the Province of Girona, northeastern Spain, between 1994 and 2008 according to the WHO 2001 classification; and b) to predict the number of MMs cases in Spain during 2013. Data were extracted from the population-based Girona Cancer Registry (GCR) located in the north-east of Catalonia, Spain, and covering a population of 731,864 inhabitants (2008 census). Cases were registered according to the rules of the European Network for Cancer Registries and the Manual for Coding and Reporting Haematological Malignancies (HAEMACARE project). To ensure the complete coverage of MMs in the GCR, and especially myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), a retrospective search was performed. The ICD-O-2 (1990) codes were converted into their corresponding ICD-O-3 (2000) codes, including MDS, polycythemia vera (PV) and essential thrombocythemia (ET) as malignant diseases. Results of crude rate (CR) and European standardized incidence rate (ASRE) were expressed per 100,000 inhabitants/yea

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

“…Regarding the prognostic models to estimate the risk in patients with CMML, MDAPS (median OS [95% CI]: low risk, 38 months [21‐53]; Intermediate‐1, 22 months ; Intermediate‐2, 9 months ; and High risk, 6 months [0‐16]; P < .001), CPSS (median OS [95% CI]: low risk, 75 months [18‐132]; Intermediate‐1, 24 months ; Intermediate‐2, 18 months ; and High risk, 3 months ; P < .001) and MCPS (median OS [95% CI]: low risk, 43 months [29‐58]; Intermediate, 24 months ; and High risk, 15 months ; P < .001) were significantly associated with OS. Although CPPS was capable to segregate the patients into four prognostic categories for OS, the MDAPS was not capable to significantly discriminate between low and intermediate‐1 group ( P = .152) and the MCPS could not differentiate between low and intermediate‐risk group ( P = .375).…”

“…Median age at diagnosis of CMML is between 72‐76 years with a male preponderance . CMML patients usually presents with cytopenia, monocytosis, and splenomegaly.…”

Myelofibrosis patients in Belgium: disease characteristics

“…6 Published data on the incidence and prevalence of MF in Europe are limited. 5,[7][8][9][10] Estimates of the annual incidence of MF in Europe range between 0.3 and 0.6 cases per 100 000 persons. 5,[7][8][9] MF is most commonly diagnosed in patients over the age of 50, 7,9 and appears to be more frequent in men.…”

“…5,[7][8][9][10] Estimates of the annual incidence of MF in Europe range between 0.3 and 0.6 cases per 100 000 persons. 5,[7][8][9] MF is most commonly diagnosed in patients over the age of 50, 7,9 and appears to be more frequent in men. 5,[7][8][9] Well-established factors predictive of a poor prognosis of MF include age (.65 years), hemoglobin concentration (,10 g/dl), leucocyte count (.25610 9 /l), circulating blasts (.1%) and the presence of one or more constitutional symptoms.…”

“…5,[7][8][9] MF is most commonly diagnosed in patients over the age of 50, 7,9 and appears to be more frequent in men. 5,[7][8][9] Well-established factors predictive of a poor prognosis of MF include age (.65 years), hemoglobin concentration (,10 g/dl), leucocyte count (.25610 9 /l), circulating blasts (.1%) and the presence of one or more constitutional symptoms. Based on these factors, the international prognostic scoring system (IPSS) and the dynamic international prognostic scoring system (DIPSS) stratify MF patients into four groups: Low, Intermediate-1 (Int-1), Intermediate-2 (Int-2) and High risk.…”